Frontiers in Endocrinology

SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes

By Xiancong Fang, Rong Li, Shengbin Liu, Yalun Yang

ReviewInterventions

The paper

Xiancong Fang, Rong Li, Shengbin Liu, Yalun Yang

Huizhou Central People's Hospital

Frontiers in Endocrinology, 4 Sep 2026

doi.org/10.3389/fendo.2026.1930813 PubMed 42761086

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19